DURHAM, N.C., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX ) , announced that they have advanced their biomarker discovery collaboration with Adaptive Biotechnologies. Adaptive will use its patented immune profiling assay, immunoSEQ™, to enable an in-depth characterization of the immune response to Heat’s ImPACT and ComPACT -based immunotherapies, including HS-410, Heat’s Phase 2 product candidate for non-muscle invasive bladder cancer. The immunoSEQ Assay, when used to evaluate the mechanism of action of the ImPACT platform, provides a significant biomarker identification opportunity to better select patients and accelerate future enrollment based on immune status.
“Previously reported data using Adaptive’s immunoSEQ Assay, demonstrated a trend between established anti-tumor immune responses and clinical outcomes with HS-410,” stated Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer. “The Adaptive Assay allows us to quantify the clonality of a T-cell response generated by our ImPACT platform. Future work should continue to be fruitful as we advance our understanding of the patients that benefit most from treatment.”
About Heat Biologics, Inc. Heat Biologics, Inc. (Nasdaq: HTBX ) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT , form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); T cell co-stimulation to further enhance patients’ immune response; and reversal of tumor-induced immune suppression. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com .
Forward Looking Statements This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for the exploration of immune response to identify patient populations more likely to respond to Heat’s therapies, These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of immunoSEQ™ and Heat's ImPACT and ComPACT therapies to perform as designed, the ability to enroll patients and complete the clinical trials on time, the other factors described in our annual report on Form 10-K for the year ended December 31, 2015 and Heat's other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
CONTACT: For Investor Inquiries: David Waldman 919-240-7133 Investorrelations@heatbio.com For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 deanne@planetcommunications.nyc
